Early access
Sign in
Taking peopleNo phase

Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer

Key facts

Who runs it
Sahlgrenska University Hospital
Where
Sweden1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
160 people, planned
Started
19 Mar 2026
Expected to end
25 Mar 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • primary RPLND for low-stage metasatatic seminoma
  • 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP)
Record updated
27 March 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A/B (maximum 2 nodes, <30 mm in any dimension)
  • Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, <30 mm in any dimension)
  • Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)

Who cannot take part

  • Previous chemotherapy (including adjuvant chemotherapy at diagnosis)
  • Previous RPLND
  • Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:

Read full original descriptionShow less

Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?

The 2 groups in the trial

  • Surgery groupExisting treatment, for comparison

    Undergoing primary RPLND

    Treatment: primary RPLND for low-stage metasatatic seminoma

  • Chemotherapy groupExisting treatment, for comparison

    Receiving chemotherapy

    Treatment: 3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease
Record updated
27 March 2026
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer (NCT07498959) – Frontlight Research